TerminatedPhase 1NCT02116959

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Studying Hereditary retinoblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Anuradha Banerjee, MD
University of California, San Francisco
Intervention
Melphalan(drug)
Enrollment
6 enrolled
Eligibility
18 years · All sexes
Timeline
20142019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02116959 on ClinicalTrials.gov

Other trials for Hereditary retinoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary retinoblastoma

← Back to all trials